Colorectal Cancer Drugs Market to Reach $25.4 Billion by 2035

Colorectal cancer drugs market was valued at $12.3 billion in 2025 and is projected to reach $25.4 billion by 2035, growing at a CAGR of 7.6%. This growth is largely driven by the increasing global burden of colorectal cancer, which remains one of the most prevalent and life-threatening malignancies worldwide. Rising incidence rates, particularly among aging populations and in developing economies, are accelerating the demand for effective treatment solutions. Lifestyle-related risk factors such as unhealthy diets, physical inactivity, smoking, and increasing obesity levels are contributing to the growing prevalence of colorectal cancer. As a result, there is a strong shift toward advanced treatment approaches, including targeted therapies and immunotherapies. These therapies offer improved precision, enhanced efficacy, and better patient outcomes compared to conventional chemotherapy, making them increasingly preferred in clinical practice.

Browse the full report description of “Colorectal Cancer Drugs Market Size, Share & Trends Analysis Report by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy), by Route of Administration (Oral, Injectable), by Disease Stage (Early-stage, Locally Advanced, Metastatic), and Forecast Period (2026–2035)” a https://www.omrglobal.com/industry-reports/colorectal-cancer-drugs-market

Leading Players Accelerate Innovation in the Colorectal Cancer Drugs Market

The key players in the colorectal cancer drugs market include Roche Holding AG, Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company, among others. These companies are driving advancements in targeted therapies and immuno-oncology treatments through the development of novel biologics, small-molecule drugs, and combination therapies. Their innovations focus on improving patient survival rates, reducing side effects, and addressing unmet medical needs, supporting evolving treatment protocols and global healthcare standards.

• In March 2026, Roche Holding AG are actively expanding their biologics manufacturing capacities between 2024 and 2025 to meet the rising global demand for oncology treatments. These investments are strengthening the supply of innovative biologic drugs, including monoclonal antibodies and combination therapies, which play a critical role in colorectal cancer management. Moreover, increasing healthcare expenditures and advancements in diagnostic infrastructure are facilitating early detection and timely intervention.

• In February 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-authorized test.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
• By Therapy
• By Route of Administration
• By Disease Stage
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape: Roche Holding AG, Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year
• Which segment and region will project the fastest growth in the market?
• Whis the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Colorectal Cancer Drugs Market Report Segment

By Therapy

• Chemotherapy
• Targeted Therapy
• Immunotherapy

By Route of Administration

• Oral
• Injectable

By Disease Stage

• Early-stage (Stage I–II)
• Locally Advanced (Stage III)
• Metastatic (Stage IV)

Global Colorectal Cancer Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/colorectal-cancer-drugs-market